Related Experiment Video
Updated: Dec 8, 2025

Structure and Coordination Determination of Peptide-metal Complexes Using 1D and 2D 1H NMR
Published on: December 16, 2013
Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Lydia Boike1, Alexander G Cioffi1, Felix C Majewski1
1Department of Chemistry, University of California, Berkeley, Berkeley, CA 94720, USA; Novartis-Berkeley Center for Proteomics and Chemistry Technologies, Berkeley, CA 94720, USA.
Abstract:
MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a cysteine-reactive covalent ligand screen to identify compounds that could disrupt the binding of MYC to its DNA consensus sequence in vitro and also impair MYC transcriptional activity in situ in cells. We have identified a covalent ligand, EN4, that targets cysteine 171 of MYC within a predicted intrinsically disordered region of the protein. We show that EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. We also show initial structure-activity relationships of EN4 and identify compounds that show improved potency. Overall, we identify a unique ligandable site within an intrinsically disordered region of MYC that leads to inhibition of MYC transcriptional activity.
Insights
Researchers developed a new covalent ligand, EN4, to target the MYC oncoprotein. This compound disrupts MYC
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- MYC is a critical oncogenic driver in numerous human cancers.
- Its intrinsically disordered nature makes direct targeting challenging.
- Targeting MYC is crucial for developing new cancer therapies.
Purpose of the Study:
- To identify novel compounds that can disrupt MYC's DNA binding and transcriptional activity.
- To explore the potential of targeting intrinsically disordered regions of MYC.
- To develop a new therapeutic strategy against MYC-driven cancers.
Main Methods:
- Cysteine-reactive covalent ligand screening was employed.
- In vitro assays assessed MYC-DNA binding disruption.
- In situ cellular assays evaluated MYC transcriptional activity inhibition.
- Structure-activity relationships of identified compounds were analyzed.
Main Results:
- A covalent ligand, EN4, was identified, targeting MYC at cysteine 171.
- EN4 demonstrated direct targeting of MYC in cells.
- The compound reduced MYC and MAX thermal stability.
- EN4 inhibited MYC transcriptional activity and downregulated target genes, impairing tumorigenesis.
- Improved potency was observed with related compounds.
Conclusions:
- A unique, ligandable site within MYC's intrinsically disordered region was identified.
- EN4 effectively inhibits MYC transcriptional activity and tumorigenesis.
- This approach offers a promising strategy for targeting MYC in cancer treatment.
Related Concept Videos
Ligand Binding and Linkage
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...

